Lerman S J, Walker R A
Clin Pediatr (Phila). 1982 Jul;21(7):409-14. doi: 10.1177/000992288202100704.
Giardia lamblia has emerged as the most common intestinal parasite in the United States. This article presents a brief review of the clinically important aspects of giardiasis and evaluates the currently used therapeutic agents. Three drugs have been advocated for the treatment of giardiasis; furazolidone (Furoxone), metronidazole (Flagyl), and quinacrine (Atabrine). None of them, however, is ideal. Metronidazole and quinacrine are more effective than furazolidone, but furazolidone has the advantage of a liquid formulation that makes administration to children easier. Quinacrine is much less expensive than the other two agents but has a somewhat higher rate of side effects and a bitter taste. There is concern about the carcinogenic potential of furazolidone and metronidazole, but this has not been evaluated for quinacrine. In the balance, we conclude that quinacrine is probably the preferable drug to use in the pediatric age group because of proven effectiveness and lower cost.
贾第虫已成为美国最常见的肠道寄生虫。本文简要回顾了贾第虫病的临床重要方面，并评估了目前使用的治疗药物。有三种药物被推荐用于治疗贾第虫病：呋喃唑酮（痢特灵）、甲硝唑（灭滴灵）和奎纳克林（阿的平）。然而，它们都不理想。甲硝唑和奎纳克林比呋喃唑酮更有效，但呋喃唑酮具有液体制剂的优势，便于给儿童用药。奎纳克林比其他两种药物便宜得多，但副作用发生率略高且味道苦涩。人们担心呋喃唑酮和甲硝唑的致癌潜力，但尚未对奎纳克林进行评估。权衡之下，我们得出结论，由于已证实的有效性和较低的成本，奎纳克林可能是儿科年龄组中更适合使用的药物。
